One of the current top-performing autoimmune disease biotech firms in the market, at least in terms of performance, is TG Therapeutics (NASDAQ: TGTX). Throughout the first half of 2019, TG Therapeutics was one of the most promising biotech stocks in the sector, with shares rising by as much as 224% between February and July. However, this all seemed to change in Q3 as the stock has quickly given back the majority of its previous gains, falling 42% since early July.
While it's normal in the world of biotech for stocks to rise and fall significantly over a short period of time, some investors are wondering whether the stock is still a good buy at its reduced price. Below we'll look at a few reasons why this company may or may not be a better buy now that its price has fallen significantly.
IMAGE SOURCE: GETTY IMAGES.
Source Fool.com